AREC.LSE Arecor Therapeutics PLC

Healthcare Biotechnology London Exchange
0.8250 GBX
Close of Nov 3, 2026
55.27 95.00
Market cap
GBX 37.4M
P/E
82.5x
P/B
10.14x
ROE
-323.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is AREC.LSE undervalued?

Graham number

The Graham number of Arecor Therapeutics PLC cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arecor Therapeutics PLC fundamental analysis

No fundamental analysis for Arecor Therapeutics PLC yet.

Arecor Therapeutics PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arecor Therapeutics PLC

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics p…

Full company profile